Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Clinics and Research in Hepatology and Gastroenterology

Volumn 41, Issue 3, 2017, Pages 284-295

  Dong, Yajie ^a   Lv, Qingguo ^a   Li, Sheyu ^a   Wu, Yuan ^a   Li, Ling ^a   Li, Juan ^a   Zhang, Fang ^a   Sun, Xin ^a   Tong, Nanwei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; PLACEBO; ANTILIPEMIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ABDOMINAL PAIN; ACUTE PANCREATITIS; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COCHRANE LIBRARY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EMBASE; FIBROSIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INFLAMMATION; LIVER HISTOLOGY; MEDLINE; META ANALYSIS; METABOLISM; MIGRAINE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; AGONISTS; FATTY LIVER; OBSERVATIONAL STUDY; RISK FACTOR; TREATMENT OUTCOME;

FATTY LIVER; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOLIPIDEMIC AGENTS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 85008517602     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2016.11.009     Document Type: Article

References (67)

1. Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
2. Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34 (2011), 274–285.
3. Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
4. Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
5. Ong, J.P., Younossi, Z.M., Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis, 11, 2007 [1–16, vii].
6. Merola, J., Liapakis, A., Mulligan, D., Yoo, P., Non-alcoholic fatty liver disease following liver transplantation: a clinical review. Clin Transplant 29 (2015), 728–737.
7. Cheung, C.R., Kelly, D.A., Non-alcoholic fatty liver disease in children. BMJ, 343, 2011, d4460.
8. Cusi, K., Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology, 142, 2012 [711–25.e6].
9. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001), 1844–1850.
10. Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
11. Amori, R.E., Lau, J., Pittas, A.G., Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298 (2007), 194–206.
12. Vilsboll, T., Christensen, M., Junker, A.E., Knop, F.K., Gluud, L.L., Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ, 344, 2012, d7771.
13. Zhang, F., Tong, Y., Su, N., Li, Y., Tang, L., Huang, L., et al. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: a systematic review and meta-analysis of randomized controlled trials. J Diabetes 7 (2015), 329–339.
14. Gluud, L.L., Knop, F.K., Vilsboll, T., Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open, 4, 2014, e005325.
15. Gupta, N.A., Mells, J., Dunham, R.M., Grakoui, A., Handy, J., Saxena, N.K., et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51 (2010), 1584–1592.
16. Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 54 (2011), 1214–1223.
17. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62 (2009), 1006–1012.
18. Sanyal, A.J., Brunt, E.M., Kleiner, D.E., Kowdley, K.V., Chalasani, N., Lavine, J.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54 (2011), 344–353.
19. Furlan, A.D., Pennick, V., Bombardier, C., van Tulder, M., 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 34 (2009), 1929–1941.
20. Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25 (2010), 603–605.
21. Higgins, J., Deeks, J.J., Selecting studies and collecting data. Higgins, J.P., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions: Cochrane Book Series, 2008, John Wiley & Sons, Ltd, Chichester, UK, 151–185.
22. Higgins, J., Deeks, J.J., Altman, D.G., Special topics in statistics. Higgins, J.P., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions: Cochrane Book Series, 2008, John Wiley & Sons, Ltd, Chichester, UK, 481–529.
23. Mai, J., Li, H., Fang, J., Liu, X., Rao, X., Estimation of fail-safe number in meta-analysis. J Evid Based Med 6 (2006), 297–303.
24. Atkins, D., Best, D., Briss, P.A., Eccles, M., Falck-Ytter, Y., Flottorp, S., et al. Grading quality of evidence and strength of recommendations. BMJ, 328, 2004, 1490.
25. Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
26. Fan, H., Pan, Q., Xu, Y., Yang, X., Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metabol 57 (2013), 702–708.
27. Shao, N., Kuang, H.Y., Hao, M., Gao, X.Y., Lin, W.J., Zou, W., Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev 30 (2014), 521–529.
28. Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal, 2012, 2012, 496453.
29. Kenny, P.R., Brady, D.E., Torres, D.M., Ragozzino, L., Chalasani, N., Harrison, S.A., Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 105 (2010), 2707–2709.
30. Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 45 (2015), 269–278.
31. Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362 (2010), 1675–1685.
32. Lavine, J.E., Schwimmer, J.B., Van Natta, M.L., Molleston, J.P., Murray, K.F., Rosenthal, P., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305 (2011), 1659–1668.
33. Singh, S., Khera, R., Allen, A.M., Murad, M.H., Loomba, R., Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 62 (2015), 1417–1432.
34. Klein, E.A., Thompson, I.M. Jr., Tangen, C.M., Crowley, J.J., Lucia, M.S., Goodman, P.J., et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 306 (2011), 1549–1556.
35. Miller, E.R., Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J., Guallar, E., Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 (2005), 37–46.
36. Bjelakovic, G., Nikolova, D., Gluud, L.L., Simonetti, R.G., Gluud, C., Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297 (2007), 842–857.
37. Guallar, E., Stranges, S., Mulrow, C., Appel, L.J., Miller, E.R., Enough is enough: stop wasting money on vitamin and mineral supplements. Ann Intern Med 159 (2013), 850–851.
38. Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006), 2297–2307.
39. Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R., Hanefeld, M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (2009), 2125–2135.
40. Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
41. Hiatt, W.R., Kaul, S., Smith, R.J., The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience. N Engl J Med 369 (2013), 1285–1287.
42. Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
43. Leuschner, U.F., Lindenthal, B., Herrmann, G., Arnold, J.C., Rossle, M., Cordes, H.J., et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 52 (2010), 472–479.
44. Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 54 (2011), 1011–1019.
45. Masterton, G.S., Plevris, J.N., Hayes, P.C., Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 31 (2010), 679–692.
46. Zelber-Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y., Santo, M., et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4 (2006), 639–644.
47. Tang, W., Xu, Q., Hong, T., Tong, G., Feng, W., Shen, S., et al. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Diabetes Metab Res Rev 32 (2016), 200–216.
48. Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann-Heurtier, A., Serfaty, L., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135 (2008), 100–110.
49. Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., Lenaour, G., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51 (2010), 445–453.
50. Carbone, L.J., Angus, P.W., Yeomans, N.D., Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 31 (2016), 23–31.
51. Promrat, K., Kleiner, D.E., Niemeier, H.M., Jackvony, E., Kearns, M., Wands, J.R., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51 (2010), 121–129.
52. Astrup, A., Rossner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374 (2009), 1606–1616.
53. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373 (2015), 11–22.
54. Su, N., Li, Y., Xu, T., Li, L., Kwong, J.S., Du, H., et al. Exenatide in obese or overweight patients without diabetes: a systematic review and meta-analyses of randomized controlled trials. Int J Cardiol 219 (2016), 293–300.
55. Bjerre Knudsen, L., Madsen, L.W., Andersen, S., Almholt, K., de Boer, A.S., Drucker, D.J., et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151 (2010), 1473–1486.
56. ® (liraglutide injection): human relevance of rodent thyroid C-cell tumors. 2009 http://www.fda.gov/downloads/AdvisoryCommittees/Committees%20MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM151129.pdf [accessed 14.12.10].
57. ® (liraglutide) US SPC. 2011 http://www.novo-pi.com/victoza.pdf [accessed 04.10.11].
58. Elashoff, M., Matveyenko, A.V., Gier, B., Elashoff, R., Butler, P.C., Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141 (2011), 150–156.
59. Parks, M., Rosebraugh, C., Weighing risks and benefits of liraglutide–the FDA's review of a new antidiabetic therapy. N Engl J Med 362 (2010), 774–777.
60. Li, L., Shen, J., Bala, M.M., Busse, J.W., Ebrahim, S., Vandvik, P.O., et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ, 348, 2014, g2366.
61. Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., Mannucci, E., Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: meta-analysis of randomized clinical trials. Diabetes Obes Metab 16 (2014), 38–47.
62. Li, L., Li, S., Liu, J., Deng, K., Busse, J.W., Vandvik, P.O., et al. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord, 16, 2016, 91.
63. Chiu, W.-Y., Shih, S.-R., Tseng, C.-H., A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer. Exp Diabetes Res, 2012, 2012, 924168.
64. Chatterjee, S., Ghosal, S., Chatterjee, S., Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome. World J Diabetes 7 (2016), 441–448.
65. Armstrong, M.J., Hull, D., Guo, K., Barton, D., Hazlehurst, J.M., Gathercole, L.L., et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 64 (2016), 399–408.
66. Lambert, J.E., Ramos-Roman, M.A., Browning, J.D., Parks, E.J., Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146 (2014), 726–735.
67. Lomonaco, R., Ortiz-Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 55 (2012), 1389–1397.